Quantitating the Dose of Physical Activity in Secondary Prevention: Relation of Exercise Intensity to Survival Barry A. Franklin, PhD Mayo Clinic Proceedings

Slides:

Advertisements

Similar presentations

Angela Aziz Donnelly April 5, 2016

Advertisements

Copyright © 2012 American Medical Association. All rights reserved.

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis Stavros Stavrakis, MD The American Journal.

Hypertension JNC VIII Guidelines.

Copyright © 2011 American Medical Association. All rights reserved.

Volume 1: Chronic Kidney Disease

L-Carnitine in the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-analysis James J. DiNicolantonio, PharmD, Carl J. Lavie,

An Emerging Role of Natriuretic Peptides

Contemporary Diagnosis and Management of Unstable Angina

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Use of the Coronary Artery Calcium Score in Discussion of Initiation of Statin Therapy in Primary Prevention Erin D. Michos, MD, MHS, Michael J. Blaha,

Atrial Fibrillation in the 21st Century: A Current Understanding of Risk Factors and Primary Prevention Strategies Arthur R. Menezes, MD, Carl J. Lavie,

James H. O’Keefe, MD, Salman K. Bhatti, MD, Ata Bajwa, MD, James J

Congestive Heart Failure in Elderly Patients

Brian Radbill, MD, Barbara Murphy, MD, Derek LeRoith, MD, PhD

Joerg Herrmann, MD, Amir Lerman, MD, Nicole P

Chapter 4: Cardiovascular Disease in Patients with CKD

Sumana Narasimhan, MD, Ruth S. Weinstock, MD, PhD

Can Vitamin D Deficiency Break Your Heart?

Step Care Therapy for Hypertension in Diabetic Patients

Do higher-risk patients benefit from off-pump coronary artery bypass grafting? Evidence from an ecologic analysis of randomized trials Oliver Kuss, PhD,

Sudden Cardiac Death From the Perspective of Coronary Artery Disease

Peripheral Arterial Disease: Diagnosis and Management

Deborah J. Clegg, PhD, Michael Cody, MD, Biff F. Palmer, MD

These slides highlight a report from a presentation at the European Society of Cardiology 2003 Congress in Vienna Austria, August 30 - September 3, 2003.

Ruchi S. Gupta, MD, MPH, Ashley A

Bronze Statues by Jane DeDecker

Topical Analgesics in the Management of Acute and Chronic Pain

Cardiorespiratory Fitness: An Independent and Additive Marker of Risk Stratification and Health Outcomes Barry A. Franklin, PhD, Peter A. McCullough,

Effect of β-Adrenergic Blockers and Other Antihypertensive Drugs on the Risk of Melanoma Recurrence and Death—I Justin C. Moser, MD, Roxana S. Dronca,

Abraham Morgentaler, MD, Martin M

Impact of Statins on Physical Activity and Fitness: Ally or Adversary?

Sexual Activity and Chronic Heart Failure

Acupuncture Mayo Clinic Proceedings

Madonna della Pietá by Michelangelo

Coronary Artery Disease: A Continuum, Not a Threshold

Exercise-Based Cardiac Rehabilitation and Improvements in Cardiorespiratory Fitness: Implications Regarding Patient Benefit Barry A. Franklin, PhD Mayo.

Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization

Cardiovascular outcomes in patients with peripheral arterial disease as an initial or subsequent manifestation of atherosclerotic disease: Results from.

Contemporary Evidence-Based Guidelines

To B or Not to B: Is Non–High-Density Lipoprotein Cholesterol an Adequate Surrogate for Apolipoprotein B? Carl J. Lavie, MD, Richard V. Milani, MD, James.

Pancreatic Ductal Adenocarcinoma

2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation: Physiologic and Educational Rationale for Changes Roger D. White, MD Mayo.

Shannon M. Dunlay, MD, MS, Naveen L. Pereira, MD, Sudhir S

On Statin Treatment to Prevent Sepsis in Dialysis Patients

Peripartum Cardiomyopathy Presenting as an Acute Myocardial Infarction

Recent Temporal Changes in Atherosclerotic Cardiovascular Diseases in Ontario: Clinical and Health Systems Impact Jack V. Tu, MD, PhD, Anam M. Khan,

An Emerging Role of Natriuretic Peptides

Risks for Cardiovascular and Cardiac Deaths in Nonobese Patients With Diabetes and Coronary Heart Disease Tetsuro Tsujimoto, MD, PhD, Hiroshi Kajio,

Cardiovascular Disease in Type 2 Diabetes: A Review of Sex-Related Differences in Predisposition and Prevention Abdallah Al-Salameh, MD, Philippe Chanson,

A Perspective on the New American College of Cardiology/American Heart Association Guidelines for Cardiovascular Risk Assessment Iftikhar J. Kullo, MD,

L-Carnitine in the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-analysis James J. DiNicolantonio, PharmD, Carl J. Lavie,

Diabetic Mastopathy Mayo Clinic Proceedings

Adjunctive Therapies in the Treatment of Acute Coronary Syndromes

Abraham Morgentaler, MD, Martin M

Hepatocellular Carcinoma

Courtney Premer, PhD, Anthony J. Kanelidis, MD, Joshua M

Serial Measurement of Serum Tryptase in Angiotensin-Converting Enzyme Inhibitor- Associated Angioedema Kevin R. Regner, MD, Douglas L. Riegert-Johnson,

Ross Arena, PhD, PT, FAHA, Carl J. Lavie, MD Mayo Clinic Proceedings

Serum Alkalinization and Hydrogen-Rich Water in Healthy Men

Mantle Cell Involvement of the Spleen

Intensive Lowering of Low-Density Lipoprotein Cholesterol Levels for Primary Prevention of Coronary Artery Disease Dean G. Karalis, MD Mayo Clinic Proceedings

Brandon J. Patterson, PharmD, PhD, Debora A. Rausch, MD, Debra E

Is There an “Asymptote of Gain” Beyond Which Further Increases in Cardiorespiratory Fitness Convey No Additional Benefits on Mortality and Atrial Fibrillation?

Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization

Surviving Heart Failure: Robert L. Frye Lecture

Diagnosis and Management of Headache in Older Adults

β-Blocker Use for the Stages of Heart Failure

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Cardiovascular Epidemiology and Epidemiological Modelling

Presentation transcript:

Quantitating the Dose of Physical Activity in Secondary Prevention: Relation of Exercise Intensity to Survival Barry A. Franklin, PhD Mayo Clinic Proceedings Volume 93, Issue 9, Pages 1158-1163 (September 2018) DOI: 10.1016/j.mayocp.2018.07.014 Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 1 Unhealthy lifestyle habits lead to traditional risk factors, the progression of cardiovascular disease, and ultimately, adverse outcomes or clinical end points, with specific reference to the types of prevention interventions: primordial (prevention of risk factors), primary (treatment of risk factors), and secondary (prevention of recurrent cardiovascular events). Bona fide interventions include lifestyle modification, pharmacotherapies (eg, aspirin, β-adrenergic blockers, statins, angiotensin-converting enzyme inhibitors), and emergent or elective coronary revascularization, when clinically indicated. CHF = congestive heart failure; MI = myocardial infarction; PAD = peripheral arterial disease. From Circulation, with permission.2 Mayo Clinic Proceedings 2018 93, 1158-1163DOI: (10.1016/j.mayocp.2018.07.014) Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 2 Multiple mechanisms by which vigorous-intensity exercise training may be more effective than moderate-intensity exercise at reducing cardiovascular risk. AF = atrial fibrillation; HF = heart failure; NO = nitric oxide. Mayo Clinic Proceedings 2018 93, 1158-1163DOI: (10.1016/j.mayocp.2018.07.014) Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions

Figure 3 Relative risk of acute myocardial infarction during vigorous physical exertion (≥6 METs) according to activity status and exercise frequency (days/week). Baseline or overall risk for the active subject is approximately half that of their sedentary counterpart, 0.5 and 1.0, respectively. From Circulation, with permission.2 Mayo Clinic Proceedings 2018 93, 1158-1163DOI: (10.1016/j.mayocp.2018.07.014) Copyright © 2018 Mayo Foundation for Medical Education and Research Terms and Conditions